1183 related articles for article (PubMed ID: 9263726)
21. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
Gessoni G; Valverde S
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
[TBL] [Abstract][Full Text] [Related]
22. Mutation in blood coagulation factor V associated with resistance to activated protein C.
Bertina RM; Koeleman BP; Koster T; Rosendaal FR; Dirven RJ; de Ronde H; van der Velden PA; Reitsma PH
Nature; 1994 May; 369(6475):64-7. PubMed ID: 8164741
[TBL] [Abstract][Full Text] [Related]
23. [Activated C protein resistance: laboratory study and prevalence of the defect in the Chilean population].
Pereira J; Quiroga T; Goycoolea M; Muñoz B; Hidalgo P; Kaltwasser G; Mezzano D
Rev Med Chil; 1996 Jun; 124(6):663-8. PubMed ID: 9041721
[TBL] [Abstract][Full Text] [Related]
24. Thrombotic tendency in 75 symptomatic, unrelated patients with APC resistance.
Melichart M; Kyrle PA; Eichinger S; Rintelen C; Mannhalter C; Pabinger I
Wien Klin Wochenschr; 1996; 108(19):607-10. PubMed ID: 8921576
[TBL] [Abstract][Full Text] [Related]
25. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives.
Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Koster T; Bertina RM; Vandenbroucke JP
Thromb Haemost; 1998 Sep; 80(3):382-7. PubMed ID: 9759614
[TBL] [Abstract][Full Text] [Related]
26. Coexistence of hereditary homocystinuria and factor V Leiden--effect on thrombosis.
Mandel H; Brenner B; Berant M; Rosenberg N; Lanir N; Jakobs C; Fowler B; Seligsohn U
N Engl J Med; 1996 Mar; 334(12):763-8. PubMed ID: 8592550
[TBL] [Abstract][Full Text] [Related]
27. Female gender and resistance to activated protein C (FV:Q506) as potential risk factors for thrombosis after elective hip arthroplasty.
Svensson PJ; Benoni G; Fredin H; Björgell O; Nilsson P; Hedlund U; Nylander G; Bergqvist D; Dahlbäck B
Thromb Haemost; 1997 Sep; 78(3):993-6. PubMed ID: 9308742
[TBL] [Abstract][Full Text] [Related]
28. Longitudinal evaluation of activated protein C resistance among normal pregnancies of Hispanic women.
Fassett MJ; Bohn YC; Kuo J; Wing DA
Am J Obstet Gynecol; 2000 Jun; 182(6):1433-6. PubMed ID: 10871461
[TBL] [Abstract][Full Text] [Related]
29. [Significance of hereditary thrombophilia for risk of thrombosis with oral contraceptives].
Bauersachs R; Lindhoff-Last E; Ehrly AM; Kuhl H
Zentralbl Gynakol; 1996; 118(5):262-70. PubMed ID: 8701622
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls.
Svensson PJ; Zöller B; Dahlbäck B
Thromb Haemost; 1997 Feb; 77(2):332-5. PubMed ID: 9157592
[TBL] [Abstract][Full Text] [Related]
31. [Changes in hemostasis system in patients with hereditary thrombophilia caused by mutation of blood coagulation factor V ( factor V Leiden)].
Papaian LP; Kobilianskaia VA; Sheĭdina AM; Baranovskaia SS; Sirotkina OV; Kargin VD; Saltykova NB; Beliazo OE; Golovina OG; Papaian KA; Tarkovskaia LR
Ter Arkh; 2001; 73(7):47-51. PubMed ID: 11523408
[TBL] [Abstract][Full Text] [Related]
32. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.
Curvers J; Thomassen MC; Rimmer J; Hamulyak K; van der Meer J; Tans G; Preston FE; Rosing J
Thromb Haemost; 2002 Jul; 88(1):5-11. PubMed ID: 12152677
[TBL] [Abstract][Full Text] [Related]
33. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis.
Bertina RM; Reitsma PH; Rosendaal FR; Vandenbroucke JP
Thromb Haemost; 1995 Jul; 74(1):449-53. PubMed ID: 8578504
[TBL] [Abstract][Full Text] [Related]
34. [Comparison of three reactants for the detection of activated protein C resistance due to mutation of factor V Leiden during pregnancy].
Magdelaine A; Soubrier F; Berkane N; Uzan S; Verdy E
Ann Biol Clin (Paris); 1998; 56(4):445-50. PubMed ID: 9754280
[TBL] [Abstract][Full Text] [Related]
35. Coagulation factor V and thrombophilia: background and mechanisms.
Segers K; Dahlbäck B; Nicolaes GA
Thromb Haemost; 2007 Sep; 98(3):530-42. PubMed ID: 17849041
[TBL] [Abstract][Full Text] [Related]
36. Thrombophilias and recurrent pregnancy loss.
Kutteh WH; Triplett DA
Semin Reprod Med; 2006 Feb; 24(1):54-66. PubMed ID: 16418978
[TBL] [Abstract][Full Text] [Related]
37. Low prevalence of factor V:Q506 in 41 patients with isolated pulmonary embolism.
Martinelli I; Cattaneo M; Panzeri D; Mannucci PM
Thromb Haemost; 1997 Mar; 77(3):440-3. PubMed ID: 9065990
[TBL] [Abstract][Full Text] [Related]
38. Resistance to activate protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays, pros and cons.
Dahlbäck B
Thromb Haemost; 1995 May; 73(5):739-42. PubMed ID: 7482395
[No Abstract] [Full Text] [Related]
39. Ischaemic stroke in infancy and childhood: role of the Arg506 to Gln mutation in the factor V gene.
Nowak-Göttl U; Sträter R; Dübbers A; Oleszuk-Raschke K; Vielhaber H
Blood Coagul Fibrinolysis; 1996 Oct; 7(7):684-8. PubMed ID: 8958390
[TBL] [Abstract][Full Text] [Related]
40. Comparison of functional testing for resistance to activated protein C and molecular biological testing for factor V R506Q in 370 patients.
Montes MA; Fox EA; Longtine JA; Dorfman DM
Arch Pathol Lab Med; 1998 Apr; 122(4):325-9. PubMed ID: 9648899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
